Skip to main content

Principal Investigator: Vimal Derebail, MD, MPH
Sponsor: National Institute of Health
Age Range: 18-79
Status: Enrolling

Purpose: The purpose of this pilot research study is to determine how the anti-clotting action of the drug apixaban is affected in patients with biopsy proven nephrotic syndrome (minimal change disease, membranous nephropathy, or focal segmental glomerulosclerosis), depending on the amount of protein in the urine, level of albumin in the blood and level of kidney function.

Study Procedures: Participants will take one dose of apixaban. Blood and urine samples will be obtained for research on day 1 and day 2. A follow-up call 48 hours after drug administration will ensure that no complications have occurred.

Participation: Participants will have two study visits. The first visit will require a whole day at the research center. The second visit will occur the next day, to collect a 24 hour urine collection and have a blood draw done 24 hours after the one dose of apixaban. The follow up phone call will last about 5 minutes.

For more information, please contact:

Dr. Vimal Derebail